Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial - The Lancet Oncology
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a...
Our findings suggested that a so-called sandwich approach involving toripalimab (in the neoadjuvant and adjuvant phases)...
www.thelancet.com
Empieza la cuenta atrás para el II Congreso de la Fundación de Tratamiento de Tumores de Cabeza y Cuello. ¡Dentro de un mes nos vemos en Madrid! Consulta el programa y resto de información en https://fundacionttcc.com
@_SEOM
@SEOR_ESP
@SEORLCCC
@SECOMmxf @ttccgroup
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer | Journal of Clinical Oncology
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck...
PURPOSEDespite advances in immunotherapy, unresectable recurrent/metastatic head and neck cancer (HNC) carries a poor prog...
ascopubs.org
Encouraging results combining cabozantinib with anti-PD1 in HNSCC. Would be great to have a biomarker of efficacy to de-risk phase 3 given LEAP-10 data.
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial - The Lancet Oncology
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a...
Our findings suggested that a so-called sandwich approach involving toripalimab (in the neoadjuvant and adjuvant phases)...
www.thelancet.com
Empieza la cuenta atrás para el II Congreso de la Fundación de Tratamiento de Tumores de Cabeza y Cuello. ¡Dentro de un mes nos vemos en Madrid! Consulta el programa y resto de información en https://fundacionttcc.com
@_SEOM
@SEOR_ESP
@SEORLCCC
@SECOMmxf @ttccgroup
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer | Journal of Clinical Oncology
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck...
PURPOSEDespite advances in immunotherapy, unresectable recurrent/metastatic head and neck cancer (HNC) carries a poor prog...
ascopubs.org
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial - The Lancet Oncology
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a...
Our findings suggested that a so-called sandwich approach involving toripalimab (in the neoadjuvant and adjuvant phases)...
www.thelancet.com
Empieza la cuenta atrás para el II Congreso de la Fundación de Tratamiento de Tumores de Cabeza y Cuello. ¡Dentro de un mes nos vemos en Madrid! Consulta el programa y resto de información en https://fundacionttcc.com
@_SEOM
@SEOR_ESP
@SEORLCCC
@SECOMmxf @ttccgroup
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer | Journal of Clinical Oncology
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck...
PURPOSEDespite advances in immunotherapy, unresectable recurrent/metastatic head and neck cancer (HNC) carries a poor prog...
ascopubs.org
TTCC en cifras
Entidades Colaboradoras
